Literature DB >> 12354834

Imaging evaluation of hepatocellular carcinoma.

Ihab R Kamel1, David A Bluemke.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer death worldwide. Numerous surgical and nonsurgical treatment options are available for treating patients with HCC. Successful long-term outcome is dependent on early detection and accurate delineation of the number and location of tumor nodules. Noninvasive imaging modalities, including ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography, are commonly used in the initial evaluation of these patients. Herein, the authors present the different manifestations of HCC with these imaging modalities and the role of imaging in the follow-up of patients after nonsurgical treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12354834     DOI: 10.1016/s1051-0443(07)61784-9

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  4 in total

1.  MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation.

Authors:  Gerrit H van de Maat; Peter R Seevinck; Mattijs Elschot; Maarten L J Smits; Hendrik de Leeuw; Alfred D van Het Schip; Maarten A D Vente; Bernard A Zonnenberg; Hugo W A M de Jong; Marnix G E H Lam; Max A Viergever; Maurice A A J van den Bosch; Johannes F W Nijsen; Chris J G Bakker
Journal:  Eur Radiol       Date:  2012-09-27       Impact factor: 5.315

2.  Hepatocellular carcinoma - issues in imaging.

Authors:  C H Thng; Y T Kuo
Journal:  Cancer Imaging       Date:  2004-10-20       Impact factor: 3.909

Review 3.  Yttrium-90 radioembolization of liver tumors: what do the images tell us?

Authors:  Pavel Singh; Gopinathan Anil
Journal:  Cancer Imaging       Date:  2014-01-03       Impact factor: 3.909

Review 4.  Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.

Authors:  A Kornberg
Journal:  ISRN Hepatol       Date:  2014-03-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.